InspireMD Reports Third Quarter 2022 Financial Results and Provides Business Update
08 nov. 2022 07h00 HE
|
InspireMD, Inc.
- Generated 38.8% growth in CGuard™ revenue year-over-year - - Continued enrollment in the C-Guardian US IDE trial, with 24 sites currently enrolling patients; on track to complete...
InspireMD to Report Third Quarter 2022 Financial Results on November 8, 2022, and Provide Corporate Business Update
25 oct. 2022 08h00 HE
|
InspireMD, Inc.
TEL AVIV, Israel, Oct. 25, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease...
InspireMD Announces Late-Breaking Presentation of Early SIBERIA Clinical Trial Results to be Featured in an e-Course at EuroPCR
25 juin 2020 10h00 HE
|
InspireMD, Inc.
TEL AVIV, Israel, June 25, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid...
InspireMD Announces Publication of 12-Month Results of CGuard™ EPS PARADIGM Trial in EuroIntervention
10 juin 2020 08h00 HE
|
InspireMD, Inc.
Results indicate that 12 months after carotid intervention the CGuard EPS MicroNET-covered stent delivers sustained protection against postprocedural neurologic events TEL AVIV, Israel, June 10,...
InspireMD, Inc. Announces Underwriter Exercise of Over-Allotment Option in Full and Closing of $11.5 Million Follow-On Underwritten Public Offering
08 juin 2020 08h00 HE
|
InspireMD, Inc.
TEL AVIV, Israel, June 08, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by...
InspireMD, Inc. Announces Pricing of $10 Million Underwritten Public Offering
03 juin 2020 07h40 HE
|
InspireMD, Inc.
TEL AVIV, Israel, June 03, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid...
InspireMD Announces First Quarter 2020 Financial Results
12 mai 2020 07h00 HE
|
InspireMD, Inc.
First quarter revenue growth driven by continued strong uptake of the CGuard™ Embolic Prevention System (EPS) in the company’s major markets Management to host investor conference call today,...
InspireMD to Report First Quarter 2020 Financial Results and Provide Business Update on Tuesday, May 12
05 mai 2020 08h00 HE
|
InspireMD, Inc.
TEL AVIV, Israel, May 05, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid...
InspireMD Announces Fourth Quarter and Year-End 2019 Financial Results
10 mars 2020 08h00 HE
|
InspireMD, Inc.
Robust CGuard™ EPS year-over-year revenue growth of 31% Management to host investor conference call today, March 10, at 8:30am ET TEL AVIV, Israel, March 10, 2020 (GLOBE NEWSWIRE) -- InspireMD,...
InspireMD to Report Fourth Quarter 2019 Financial Results and Provide Business Update on Tuesday, March 10
03 mars 2020 08h00 HE
|
InspireMD, Inc.
TEL AVIV, Israel, March 03, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid...